



Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials

December 15, 2009

Expanded Thomson Pharma offering now available

PHILADELPHIA and LONDON, Dec 15, 2009 /PRNewswire via COMTEX/ -- Thomson Reuters today announced that Thomson Pharma(R) has become the first drug pipeline database to fully integrate detailed clinical trial protocol and outcome information. This highly anticipated new content is being provided to all Thomson Pharma customers this month.

Thomson Pharma will offer drug related clinical trial intelligence from registries, publications, press releases, conferences, and other sources across all therapeutic areas. It includes some of the most advanced searching capabilities on the market, enabling identification of trials based on over twenty criteria that are individually indexed by experts. This includes not only trial criteria such as drug, phase and recruitment status, but also scientific criteria such as mechanism of action, target and biomarker.

"We are proud to be the first to integrate drug pipeline content with robust clinical trial content in a single competitive intelligence solution," said Wendy Hamilton, vice president of product strategy at Thomson Reuters. "This not only addresses our customers' needs for increased efficiency and new competitive insights, but also ensures that Thomson Pharma will remain the most comprehensive single solution for pharmaceutical competitive intelligence on the market."

Thomson Pharma covers the entire drug discovery and development pipeline -- the drugs, compounds, targets, companies, clinical trials, patents, journals, conferences, academic articles and more. For more information, please visit: go.thomsonreuters.com/thomsonpharma.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE: TRI). For more information, go to www.thomsonreuters.com.

SOURCE Thomson Reuters

<http://www.thomsonreuters.com>